Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the fourth quarter and year ended December 31, 2010.

"As we begin 2011, we believe Anadys is well-positioned to create value in the evolving HCV landscape," said Steve Worland, Ph.D., President and CEO of Anadys.  "Last year, we demonstrated important safety and efficacy parameters for ANA598 in combination with current treatment over twelve weeks. We look to extend these results with the recently initiated Phase IIb study which should set the stage for Phase III development.  Additionally, we plan to advance ANA773, our oral interferon inducer being developed as a pan-genotypic agent for HCV."

Development Program HighlightsANA598

  • Phase IIb Study Underway Dosing has begun in the Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin (SOC) for the treatment of chronic hepatitis C (HCV).  ANA598, the Company's direct-acting antiviral (DAA), is being tested in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.
  • 2011 Milestones – The Company expects to receive Week 8 antiviral response data for treatment-naive patients by the end of the second quarter of 2011, Week 12 antiviral response data for treatment-experienced patients in the third quarter of 2011 and Week 24 antiviral response data for both groups in the fourth quarter of 2011. 
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
    2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
    3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
    4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
    5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
    6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
    7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
    8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
    9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
    10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
    11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
    (Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
    (Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
    (Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
    Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
    ... Fuel Cell Technology On The Ground in Los Angeles and planned for New ... ... ... Virgin Atlantic, one of,the world,s leading long-haul airlines, and General Motors, the world,s,largest automaker, ...
    ... Company,s Leading microRNA Intellectual ... Property Position ... Allowed Patents, and More Than 60 Pending Patent ... Rosetta Genomics, Ltd. (NASDQ: ROSG) announced,today that the U.S. Patent and ...
    ... Anatomic Pathology LIS Interface to Digital Pathology Information ... ... March 3 IMPAC Medical,Systems, Inc. (IMPAC), an Elekta company ... laboratories,and Aperio Technologies, (Aperio) a global leader in digital pathology ...
    Cached Biology Technology:Virgin Atlantic to Offer Zero-Emissions GM Hydrogen Fuel Cell Limousines to Upper Class Passengers 2Virgin Atlantic to Offer Zero-Emissions GM Hydrogen Fuel Cell Limousines to Upper Class Passengers 3Rosetta Genomics Announces Allowance of Two Additional microRNA Patents 2Rosetta Genomics Announces Allowance of Two Additional microRNA Patents 3Rosetta Genomics Announces Allowance of Two Additional microRNA Patents 4IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 2IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 3
    (Date:7/11/2014)... Standards and Technology (NIST) need a special tool ... prove that necessity is truly the mother of ... Lorna De Leoz and Stephen Stein, NIST chemists ... is the study of the abundant, often-branched sugar ... and lipids and influence cellular processes, including immunity, ...
    (Date:7/11/2014)... An international team of researchers, including scientists from the ... just a reported a major step in understanding photosynthesis, ... now maintains the oxygen in its atmosphere and which ... on earth. , The researchers report the first ... reaction, namely the step in which a specific protein ...
    (Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
    Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
    ... To most people in the southwestern U.S., the April 4 ... But on a group of inch-long fish that exist nowhere ... the ground in Nevada,s Mojave Desert, it unleashed a veritable ... the event on cameras installed above and below the water,s ...
    ... (EPA) has awarded nearly $2.5 million to 11 ... environmental areas: monitoring and control of air emissions, ... monitoring, water infrastructure, homeland security, nanotechnology and innovation ... of concept" awards from EPA, and will use ...
    ... JOLLA, Calif., May 11, 2010 -- Investigators from around ... on Friday, May 7, to share their knowledge of ... non-coding nucleic acids turn off proteins and have been ... numerous other conditions. "The discovery that small ...
    Cached Biology News:'Tsunami' video sheds light on struggling pupfish 2'Tsunami' video sheds light on struggling pupfish 3'Tsunami' video sheds light on struggling pupfish 4'Tsunami' video sheds light on struggling pupfish 5EPA awards small businesses to develop new environmental technologies 2Researchers share insights into RNA 2
    MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
    Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
    Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
    ...
    Biology Products: